KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short term Debt: 2009-2023

Historic Short term Debt for Ionis Pharmaceuticals (IONS) over the last 14 years, with Dec 2023 value amounting to $44.3 million.

  • Ionis Pharmaceuticals' Short term Debt rose 1318.83% to $630.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.9 million, marking a year-over-year increase of 1318.83%. This contributed to the annual value of $44.3 million for FY2023, which is N/A change from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Short term Debt stood at $44.3 million for FY2023, which was up 1,157.29% from $3.5 million recorded in FY2021.
  • In the past 5 years, Ionis Pharmaceuticals' Short term Debt ranged from a high of $308.8 million in FY2020 and a low of $2.0 million during FY2019.
  • In the last 2 years, Ionis Pharmaceuticals' Short term Debt had a median value of $23.9 million in 2021 and averaged $23.9 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Short term Debt surged by 15,142.30% in 2020, and later slumped by 98.86% in 2021.
  • Yearly analysis of 4 years shows Ionis Pharmaceuticals' Short term Debt stood at $2.0 million in 2019, then surged by 15,142.30% to $308.8 million in 2020, then slumped by 98.86% to $3.5 million in 2021, then reached $44.3 million in 2023.